Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Matthias Gerlach
11.12.26 -- 5 Steps To Achieving Your Biosimilar Milestones On Time
Step-By-Step Guide To Achieving Your Biosimilar Milestones On Time As the biologic patent cliff looms, biosimilar developers must strategically plot their approach to development and manufacturing to secure a corner of their market and reach their target patients. Purdue University-based LyoHUB charts a risk-based course to modernizing freeze-drying technology for better performance and advanced modalities.
Why CMC Must Shape Critical Decisions Early In Development Original
By Matthias Gerlach, Ph.D. There is a reasonable objection to the familiar call to involve every function earlier. If CMC (chemistry, manufacturing, and controls), quality, regulatory, manufacturing, clinical, and commercial all need to be involved from the beginning, what does “early” mean? More meetings are not a development strategy. This principle applies across therapeutic modalities, even though the two examples in this article come from biologics development.
11.10.26 -- Your CDMO Quality Dashboard Is Green. What's It Hiding?
Mastering Aseptic Fill-Finish | Dec. 1, 2026, 11:00 AM ET This session explores aseptic fill-finish manufacturing, focusing on contamination control, regulatory compliance, and sterile processing best practices. Industry experts will discuss the value of early sponsor-CDMO collaboration, effective program planning, platform technologies, and quality-focused manufacturing strategies.
11.10.26 -- Is Your Supply Chain Ready For The End Of Class VI?
Webinar: Decoding Biologics Tech Transfer: Guiding process performance across sites, scales, and bioreactor systems Tech transfer isn't just moving a process from one place to another. It's about ensuring process understanding and control can withstand changes in scale, equipment, sites, and teams.
11.06.26 -- Is Your Supply Chain Ready For The End Of Class VI?
As cell and gene therapies advance toward commercialization, scalable supply chains are critical to reaching patients reliably. On November 12, 2026 at 11 AM ET join Cell & Gene Live’s Erin Harris with Lineage Cell Therapeutics CEO Brian Culley and Allogene CTO Ben Beneski to explore cryopreservation, materials planning, inventory visibility, predictive analytics, chain-of-identity, and digital infrastructure. Register now for insights on building resilient, launch-ready operations.
Is Your Supply Chain Ready For The End Of Class VI? Original
Get more Bioprocess insight with our FREE newsletter Guest Column | October 21, 2026 By Matthias Gerlach, Ph.D., independent executive advisor in pharma and biotech For years, USP Class VI has been a familiar reference in the qualification of single-use components. The latest revisions to USP general chapters <87> and <88> change that framework and raise practical questions for manufacturers relying on supplier qualification data.
10.19.26 -- The FDA's AI Religion: Elsa Dons A HALO
Why Sterile Manufacturing Matters For ADC And CDMO Success Sterile manufacturing is increasingly a strategic differentiator in drug development, particularly as antibody-drug conjugates (ADCs) add complexity to formulation, fill/finish, and lyophilization. This collection explores critical decisions around in-house manufacturing, outsourcing, and CDMO selection, alongside ADC-specific lyophilization challenges.
10.15.26 -- A Sponsor's Guide To Smarter Viral Vector CDMO Partnerships
Get more Cell & Gene insight with our FREE newsletter Newsletter | October 15, 2026 Webinar: Precision at Scale: Optimizing Cell-Free DNA Manufacturing for Next-Generation mRNA Vaccines and Therapeutics As mRNA vaccines and therapeutics advance, scalable, consistent DNA templates are increasingly important.
10.13.26 -- CDMO Selection Beyond Capabilities And Price
Secure, sustainable raw material supply is at the core of every biopharmaceutical innovation. Breakthrough therapies leveraging cell culture media depends on quality products, and companies rely on strong supplier relationships to compete in the industry. Nu-Tek BioSciences meets your supply and sustainability needs with our state-of-the-art facility and 100% animal-free products. Improve your cell culture titer and simplify your supply without compromising on quality and environmental impact.
CDMO Selection Beyond Capabilities And Price Original
By Matthias Gerlach, Ph.D., independent executive advisor in pharma and biotech Selecting a CDMO is a decision I have faced from both sides and at various inflection points, including during development, through technology transfer and scale-up, and later in commercial manufacturing and supply. In each one of these scenarios, assessment begins at determining technical fit. The site needs the right technology, equipment, and regulatory experience for the product and its stage of development.
Transactional Analysis as a Crucial Element for Employee Leadership
Transactional Analysis (TA) is a psychological model and method dating back to the 1960s. It provides a framework for analyzing human personalities and relationships. Knowledge and application of key aspects of TA are an important tools for me as a leader and employee, as well as an individual. Understanding the methods of TA has aided me in recognizing patterns and weaknesses in my communication, enabling me to interact more constructively with colleagues and team members.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Matthias
Contact Matthias, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack